Today’s late-breaking abstract session at #EHA25Virtual saw Efstathios Kastritis present exciting new data for #daratumumab in systemic light chain (AL) amyloidosis, a rare condition that can cause serious damage to multiple organs and for which there are currently no approved therapies.
– In the Phase 3 ANDROMEDA trial, the addition of daratumumab subcutaneous (SC) to cyclophosphamide-bortezomib-dexamethasone (CyBorD) resulted in deeper and more rapid haematological responses than CyBorD alone (53% vs 18%; OR, 5.1; P<0.0001) in patients with newly-diagnosed #ALamyloidosis.
– Treatment with the Dara-CyBorD combination also delayed major organ deterioration, haematological progression or death, improved event-free survival and increased cardiac and renal response rates compared to CyBorD.
– Rates of infections and serious TEAEs were higher with the Dara-CyBorD vs CyBorD, but in general the safety profile was acceptable and consistent with the known profiles of Dara SC and CyBorD.
– Overall, the data show that the Dara-CyBorD combination can significantly improve outcomes compared to CyBorD alone and suggest it may become the new standard of care.